These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 26613768)

  • 21. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.
    Rao VU; Pavlov A; Klearman M; Musselman D; Giles JT; Bathon JM; Sattar N; Lee JS
    Arthritis Rheumatol; 2015 Feb; 67(2):372-80. PubMed ID: 25332171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients.
    Schroeder LL; Tang X; Wasko MC; Bili A
    Rheumatol Int; 2015 Jun; 35(6):1059-67. PubMed ID: 25540049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis.
    Pozzi FS; Maranhão RC; Guedes LK; Borba EF; Laurindo IM; Bonfa E; Vinagre CG
    J Clin Lipidol; 2015; 9(1):72-80. PubMed ID: 25670363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.
    Kremer JM; Genovese MC; Keystone E; Taylor PC; Zuckerman SH; Ruotolo G; Schlichting DE; Crotzer VL; Nantz E; Beattie SD; Macias WL
    Arthritis Rheumatol; 2017 May; 69(5):943-952. PubMed ID: 28029752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
    Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
    Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.
    Liao KP; Rist P; Giles J; Santacroce L; Connelly MA; Glynn RJ; Ridker P; Tawakol A; Bathon J; Solomon DH
    Arthritis Res Ther; 2024 Jun; 26(1):123. PubMed ID: 38915065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A
    Kato M; Kaneko Y; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Yokota I; Atsumi T; Takeuchi T
    Mod Rheumatol; 2020 May; 30(3):442-449. PubMed ID: 31106666
    [No Abstract]   [Full Text] [Related]  

  • 33. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.
    Chen DY; Chen YM; Hsieh TY; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2015 Mar; 17(1):52. PubMed ID: 25889426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.
    Ronda N; Greco D; Adorni MP; Zimetti F; Favari E; Hjeltnes G; Mikkelsen K; Borghi MO; Favalli EG; Gatti R; Hollan I; Meroni PL; Bernini F
    Arthritis Rheumatol; 2015 May; 67(5):1155-64. PubMed ID: 25605003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    Cauza E; Cauza K; Hanusch-Enserer U; Etemad M; Dunky A; Kostner K
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1004-7. PubMed ID: 12635469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.
    Novikova DS; Popkova TV; Lukina GV; Luchikhina EL; Karateev DE; Volkov AV; Novikov AA; Aleksandrova EN; Nasonov EL
    J Korean Med Sci; 2016 Feb; 31(2):202-7. PubMed ID: 26839473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.
    Hang Y; Qin X; Ren T; Cao J
    Lipids Health Dis; 2018 Jun; 17(1):146. PubMed ID: 29935544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
    Myasoedova E; Crowson CS; Kremers HM; Roger VL; Fitz-Gibbon PD; Therneau TM; Gabriel SE
    Ann Rheum Dis; 2011 Mar; 70(3):482-7. PubMed ID: 21216812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kanayama Y; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Terabe K; Yoshioka Y; Ishiguro N
    Clin Rheumatol; 2014 Jan; 33(1):39-47. PubMed ID: 24057092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.